DILIsym®

Quantitative systems toxicology (QST) software
for drug-induced liver injury (DILI)

Click here for an overview presentation on DILIsym

Choose a Module:

 

DILIsym Services and SOLVO Biotechnology, a Charles River Laboratories company, have teamed up to create a winning combination!

SOLVO provides high quality data from their world-class laboratories to support DILIsym software representations of bile acid homeostasis and bilirubin processing via the following endpoints:

  • BSEP inhibition;
  • MRP2, MRP3 and MRP4 inhibition;
  • NTCP inhibition;
  • OATP1B1 and OATP1B3 inhibition;
  • MDR3 inhibition.

Many times, DILIsym results also help with selection of future transporter assays to be completed, making the data collection / simulation cycle iterative.

Team up with DILIsym and SOLVO today and get more information out of your data! Visit SOLVO here to get more information on their services directly, or engage them indirectly with DILIsym Services serving as your white glove, “one stop shop” project manager.

Download a poster here showing use of SOLVO data for DILIsym predictions.

What do NURTEC™ ODT, TURALIO®, lixivaptan, solithromycin, JYNARQUE®, VEKLURI®, and UBRELVY® have in common?

To learn more on the DILIsym® Applications in Drug Development, register for our 2021 DILIsym® Panel-driven Webinar on April 29. Join us for Q&A session with Dr. Vlad Coric (CEO of Biohaven Pharmaceuticals), Dr. Lorenzo Pellegrini (COO of Palladio Biosciences), Dr. Paul B. Watkins, a hepatologist and DILI experts. Register Now